#daraxonrasib is an active hashtag on Bluesky. In the last 30 days, 12 people shared 15 posts with it — around 1 a day. Activity is up 100% versus the previous week, peaking on Aug 27 with 4 posts.
www.forbes.com
FDA Approves New Pancreatic Cancer Drug After Stunning Trial Results
MedChemExpress @medchemexpress.bsky.social
The FDA has approved Rasonque (#daraxonrasib), a first-in-class, once-daily oral #RAS(ON) inhibitor, for previously treated metastatic #PDAC. In the Phase 3 RASolute 302 trial (500 patients): 🔹Overall survival: 13.2 vs. 6.7 months 🔹Risk of death reduced by ~60%
www.fr.de
Durchbruch bei Bauchspeicheldrüsenkrebs: Eine Pille verdoppelt die Überlebenszeit
Bauchspeicheldrüsenkrebs gilt als Todesurteil. Doch eine neue Pille ließ Patienten doppelt so lange leben. Dahinter steckt ein Trick aus der Natur.
Ravi 🇨🇦 @medical91.bsky.social
Promising new treatment for pancreatic cancer doubles survival rates
www.pbs.org
www.forbes.com
FDA Approves New Pancreatic Cancer Drug After Stunning Trial Results
ascopost.com
Daraxonrasib in <em>KRAS</em>-Mutant Pancreatic Cancer: A First Step in Shifting the Paradigm of Treatment
Wolpin and colleagues have demonstrated in the global randomized Phase III RASolute 302 trial that daraxonrasib, an oral RAS(ON) inhibitor, nearly doubles median overall survival in previously treated...
www.forbes.com
FDA Approves New Pancreatic Cancer Drug After Stunning Trial Results
mastodon.online
Original post on mastodon.online
shorturl.at
EARA | News - Drug doubles life expectancy of pancreatic cancer patients
The US Food and Drug Administration (FDA) has approved a drug for advanced pancreatic cancer following a phase 3 clinical trial in which patients lived twice as long as those who were treated…
www.rtl.de
→ zum Artikel
third-news.com
Revolutionary FDA-Approved Daraxonrasib Launches for Metastatic Pancreatic Cancer at Karmanos Institute
The Karmanos Cancer Institute introduces daraxonrasib (Rasonque), an FDA-approved treatment for metastatic pancreatic cancer, offering new hope to patients.
donporque.com
¿Qué fármaco casi duplica la supervivencia en cáncer de páncreas?
Rasonque casi duplica la supervivencia en cáncer de páncreas metastásico y abre una nueva vía frente a uno de los tumores de peor pronóstico.
www.forbes.com
FDA Approves New Pancreatic Cancer Drug After Stunning Trial Results
MedChemExpress @medchemexpress.bsky.social
The FDA has approved Rasonque (#daraxonrasib), a first-in-class, once-daily oral #RAS(ON) inhibitor, for previously treated metastatic #PDAC. In the Phase 3 RASolute 302 trial (500 patients): 🔹Overall survival: 13.2 vs. 6.7 months 🔹Risk of death reduced by ~60%
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.
